Irradiation-free RIC HSCT has a tolerable safety profile and is effective therapy for pediatric bone marrow failure syndromes.
Adolescent
Bone Marrow Failure Disorders
/ therapy
Child
Child, Preschool
Drug Therapy, Combination
Female
Follow-Up Studies
Graft vs Host Disease
/ prevention & control
Hematopoietic Stem Cell Transplantation
Humans
Infant
Male
Myeloablative Agonists
/ therapeutic use
Retrospective Studies
Transplantation Conditioning
/ methods
Treatment Outcome
Young Adult
HSCT
RIC
graft-vs-host disease
pediatric BMFS
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
06
06
2020
revised:
09
08
2020
accepted:
03
09
2020
pubmed:
7
10
2020
medline:
5
1
2022
entrez:
6
10
2020
Statut:
ppublish
Résumé
For patients with bone marrow failure syndromes (BMFS) who may tolerate gradual donor engraftment and achieve adequate disease control with stable mixed chimerism, RIC regimens may be preferable to myeloablative regimens. We performed a retrospective analysis of outcomes for patients who underwent HSCT at our institution between 2009 and 2017 for BMFS using an irradiation-free RIC regimen. Fourteen pediatric patients with BMFS received fludarabine (30 mg/m
Substances chimiques
Myeloablative Agonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13855Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
Koura DT, Horan JT, Langston AA, et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant. 2013;19(11):1638-1649.
Oshrine BR, Olson TS, Bunin N. Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease. Pediatr Blood Cancer. 2014;61(10):1852-1859.
Marsh RA, Rao MB, Gefen A, et al. Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transplant. 2015;21(8):1460-1470.
Kothari A, Ngwube A, Hayashi R, et al. Hematopoietic cell transplantation using reduced-intensity conditioning is successful in children with hematologic cytopenias of genetic origin. Biol Blood Marrow Transplant. 2015;21(7):1321-1325.
Ngwube A, Hayashi RJ, Murray L, et al. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatr Blood Cancer. 2015;62(7):1270-1276.
Crazzolara R, Kropshofer G, Haas OA, Matthes-Martin S, Kager L. Reduced-intensity conditioning and stem cell transplantation in infants with diamond blackfan anemia. Haematologica. 2017;102(3):e73-e75.
Andolina JR, Reinish AL, Akhtar R, et al. Successful reduced-intensity conditioning hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia in two children. Pediatr Blood Cancer. 2018;65(8):e27218.
Nikiforow N. Finding, "intermediate" ground in transplant and HLH. Blood. 2018;132(13):1361-1363.
Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48(4):537-543.
Cluzeau T, Lambert J, Raus N, et al. Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI. Bone Marrow Transplant. 2016;51(5):687-691.
Oshima K, Hanada R, Kobayashi R, et al. Hematopoietic stem cell transplantation in patients with severe congenital neutropenia: an analysis of 18 Japanese cases. Pediatr Transplant. 2010;14(5):657-663.
Fioredda F, Iacobelli S, van Biezen A, et al. Stem cell transplantation in severe congenital neutropenia: an analysis from the European society for blood and marrow transplantation. Blood. 2015;126(16):1885-1892.